enow.com Web Search

  1. Ads

    related to: revlimid approved indications for diabetes treatment guidelines

Search results

  1. Results from the WOW.Com Content Network
  2. Lenalidomide - Wikipedia

    en.wikipedia.org/wiki/Lenalidomide

    Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]

  3. Diabetes medication - Wikipedia

    en.wikipedia.org/wiki/Diabetes_medication

    Exenatide (also Exendin-4, marketed as Byetta) is the first GLP-1 agonist approved for the treatment of type 2 diabetes. Exenatide is not an analogue of GLP but rather a GLP agonist. [32] [33] Exenatide has only 53% homology with GLP, which increases its resistance to degradation by DPP-4 and extends its half-life. [34]

  4. Cereblon E3 ligase modulator - Wikipedia

    en.wikipedia.org/wiki/Cereblon_E3_ligase_modulator

    The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.

  5. Celgene Gets Positive CHMP Nod for Revlimid Label Expansion - AOL

    www.aol.com/news/celgene-gets-positive-chmp-nod...

    Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.

  6. Johnson & Johnson Diabetes Drug Approved by FDA - AOL

    www.aol.com/news/2013-03-29-johnson-johnson...

    The Food and Drug Administration has granted approval to Invokana, a Type 2 diabetes drug manufactured by a unit of Johnson & Johnson . The drug is part of a new class of treatments known as SGLT2 ...

  7. Teplizumab - Wikipedia

    en.wikipedia.org/wiki/Teplizumab

    Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes in people with stage 2 type 1 diabetes. [3] [4] [5] The Fc region of this antibody has been engineered to have Fc receptor non-binding (FNB) properties. [6]

  1. Ads

    related to: revlimid approved indications for diabetes treatment guidelines